S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
TSE:EXE

Extendicare (EXE) Price Target & Analyst Ratings

C$7.16
0.00 (0.00%)
(As of 06/2/2023 ET)
Compare
Today's Range
C$7.14
C$7.25
50-Day Range
C$6.22
C$7.28
52-Week Range
C$6.02
C$7.69
Volume
178,300 shs
Average Volume
157,169 shs
Market Capitalization
C$604.23 million
P/E Ratio
143.20
Dividend Yield
6.70%
Price Target
C$7.50

Extendicare Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 3 Analyst Ratings

Consensus Analyst Price Target

C$7.50
4.75% Upside
High PredictionC$8.00
Average PredictionC$7.50
Low PredictionC$7.00
TypeCurrent
6/3/22 to 6/3/23
1 Month Ago
5/4/22 to 5/4/23
3 Months Ago
3/5/22 to 3/5/23
1 Year Ago
6/3/21 to 6/3/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
0 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price TargetC$7.50C$7.25C$7.38C$8.43
Predicted Upside4.75% Upside7.80% Upside8.87% Upside8.97% Upside
Get Extendicare Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EXE and its competitors with MarketBeat's FREE daily newsletter.


EXE Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

EXE Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Extendicare Stock vs. The Competition

TypeExtendicareMedical Companies
Consensus Rating Score
2.00
2.66
Consensus RatingHoldBuy
News Sentiment RatingNeutral News
Positive News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/9/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector PerformC$7.00 ➝ C$7.50+6.08%
5/9/2023National Bankshares
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetSector PerformC$7.00 ➝ C$7.50+6.08%
10/20/2022TD Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetHoldC$7.50 ➝ C$7.00+1.01%
6/27/2022CIBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetC$8.50 ➝ C$8.00+13.96%
(Data available from 6/3/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












EXE Price Target - Frequently Asked Questions

What is Extendicare's consensus rating and price target?

According to the issued ratings of 3 analysts in the last year, the consensus rating for Extendicare stock is Hold based on the current 3 hold ratings for EXE. The average twelve-month price prediction for Extendicare is C$7.50 with a high price target of C$8.00 and a low price target of C$7.00. Learn more on EXE's analyst rating history.

Do Wall Street analysts like Extendicare more than its competitors?

Analysts like Extendicare less than other Medical companies. The consensus rating for Extendicare is Hold while the average consensus rating for medical companies is Buy. Learn more on how EXE compares to other companies.

Does Extendicare's stock price have much upside?

According to analysts, Extendicare's stock has a predicted upside of 6.79% based on their 12-month price targets.

What analysts cover Extendicare?

Extendicare has been rated by National Bankshares, and Royal Bank of Canada in the past 90 days.


Stock Ratings Reports and Tools

This page (TSE:EXE) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -